Page last updated: 2024-11-07

bmy 42393

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

BMY 42393: partial prostacyclin agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131961
CHEMBL ID117835
SCHEMBL ID675089
MeSH IDM0214198

Synonyms (13)

Synonym
bmy 42393
CHEMBL117835
bmy-42393
2-[3-[2-(4,5-diphenyl-1,3-oxazol-2-yl)ethyl]phenoxy]acetic acid
136451-58-6
acetic acid, (3-(2-(4,5-diphenyl-2-oxazolyl)ethyl)phenoxy)-
2-(3-(2-(4,5-diphenyl-2-oxazolyl)ethyl)phenoxy)acetic acid
SCHEMBL675089
AZZHJQQOAHWBPN-UHFFFAOYSA-N ,
2-[3-[2-(4,5-diphenyl-2-oxazolyl)-ethyl]phenoxy]acetic acid
DTXSID90159798
2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid
PD161040
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID92397In vitro inhibition of ADP-induced platelet aggregation using human platelet rich plasma2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic.
AID92396In vitro inhibition of 5.86 uM ADP-induced human platelet aggregation in platelet rich plasma (PRP)1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid.
AID711594Antiaggregatory activity in platelet rich human plasma2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID92377Inhibitory concentration for displacing [3H]iloprost from human platelet membrane at 5.4 nM at 37 degree C1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid.
AID301228Inhibition of ADP-induced platelet aggregation in human platelet rich plasma2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists.
AID160752In vitro Prostacyclin (PGI-2) receptor binding assay was determined based on displacement of [3H]iloprost radioligand from cloned human IP receptor; Not tested2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic.
AID222764In vitro inhibition of ADP-induced aggregation of human platelets1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring.
AID302640Inhibition of ADP-induced platelet aggregation in human platelet rich plasma2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Structure-activity relationship study on the 6-membered heteroaromatic ring system of diphenylpyrazine-type prostacyclin receptor agonists.
AID44748Inhibition of ADP-induced human platelet aggregation.1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives.
AID44747Inhibition of ADP-induced aggregation of human blood platelets in plasma1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moiety.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (66.67)18.2507
2000's6 (28.57)29.6817
2010's1 (4.76)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]